Amycretin
aka NNC0487-0111 · dual amylin/GLP-1 · Novo amylin
Dual amylin/GLP-1 receptor agonist from Novo Nordisk. Single molecule.
Sequence
Mechanism of action
Unimolecular agonist of both the GLP-1 receptor and the amylin (calcitonin) receptor. The GLP-1 arm enhances glucose-dependent insulin secretion and slows gastric emptying; the amylin arm reinforces satiety, giving strong appetite suppression. Available in oral and subcutaneous forms.
What the evidence actually shows
Early clinical data promising. Next-gen Novo Nordisk candidate.
Regulatory status
Dosing — what backs each figure
Amycretin is a Novo Nordisk investigational GLP-1/amylin receptor co-agonist with real, published human trial regimens: once-weekly subcutaneous dosing escalated from 0.3 mg to maintenance doses of 1.25-60 mg over 20-36 weeks, and once-daily oral dosing titrated up to 50-100 mg/day over 12 weeks. It has no marketing approval anywhere and no approved label — these are trial regimens under medical supervision, not a self-administration protocol.
Once-weekly subcutaneous amycretin escalated from 0.3 mg up to 60 mg over a total treatment duration of 36 weeks (Part B); further arms escalated from 0.3 mg to maintenance doses of 20 mg (36 weeks), 5 mg (28 weeks) or 1.25 mg (20 weeks). Part A was single ascending subcutaneous doses.
Adults aged 18-55 with overweight or obesity (BMI 27.0-39.9 kg/m2) · subcutaneous
Phase 1b/2a randomised placebo-controlled study, The Lancet 2025 (Novo Nordisk) ↗
Oral amycretin single ascending doses of 1, 3, 6, 12, 18 or 25 mg (Part A); multiple ascending oral doses of 3, 6 or 12 mg once daily for 10 days (Part B); fixed-titration once-daily oral regimens over a 12-week intervention — 3 mg up to 50 mg, 6 mg up to 2 x 50 mg (100 mg/day), and 3 mg up to 2 x 25 mg (50 mg/day)
Adults aged 18-55 with overweight or obesity (BMI 25.0-34.9 for parts A/B; 27.0-39.9 for part C/D) · oral
21 days of amycretin administration reduced total energy intake by 47% and body weight by 18%; the mg/kg dose is stated in the full text rather than the abstract
rat (diet-induced obese) and mouse · not stated in abstract (parenteral) · PMID 40706446
Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.
Handling and storage
Safety
References (2)
- Gasiorek A, et al. (2025) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗The LancetPMID 40550229DOI
First-in-human phase 1 trial of single and multiple ascending subcutaneous doses of amycretin in adults with overweight or obesity, reporting safety, tolerability, PK and PD.
- Dahl K, et al. (2025) Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗The LancetPMID 40550231DOI
Randomised placebo-controlled phase 1b/2a study in adults with BMI 27.0-39.9 kg/m2. Once-weekly subcutaneous amycretin was escalated from 0.3 mg to maintenance doses of 60 mg (36 weeks), 20 mg (36 weeks), 5 mg (28 weeks) or 1.25 mg (20 weeks); primary endpoint was treatment-emergent adverse events, with bodyweight change as a secondary endpoint.
Data provenance
Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.
Could not verify
sequence, molecularFormula, molecularWeight, casNumber, pubchemCid, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent, regulatory.wada